SCHEMBL3536583

SCHEMBL3536583

Cc1ccc(C)n1-c1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.61
MAPT P10636 11/20 0.61
LMNA P02545 2/20 0.61
CYP2C19 P33261 4/20 0.50
CYP2C9 P11712 4/20 0.50
NPSR1 Q6W5P4 3/20 0.50
CYP3A4 P08684 2/20 0.50
GAA P10253 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.48
PKM P14618 1/20 0.48
GPR119 Q8TDV5 2/20 0.47
MET P08581 1/20 0.47
HTR6 P50406 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23293433 0.87 ALDH1A1 (0.65) ALDH1A1MAPTLMNACYP2C19NPSR1
SCHEMBL31157987 0.87 ALDH1A1 (0.65) ALDH1A1MAPTLMNACYP2C19NPSR1
SCHEMBL29803559 0.85 MAPT (0.68) ALDH1A1MAPTLMNACYP2C19CYP2C9
SCHEMBL214341 0.85 MAPT (0.68) ALDH1A1MAPTLMNACYP2C19CYP2C9
SCHEMBL16270620 0.85 MAPT (0.71) ALDH1A1MAPTLMNACYP2C19NPSR1
SCHEMBL29858317 0.85 MAPT (0.71) ALDH1A1MAPTLMNACYP2C19NPSR1
SCHEMBL27691394 0.84 ALDH1A1 (0.53) ALDH1A1MAPTLMNACYP2C19CYP2C9
SCHEMBL31157984 0.84 ALDH1A1 (0.60) ALDH1A1MAPTLMNACYP2C19NPSR1
SCHEMBL31000429 0.84 ALDH1A1 (0.64) ALDH1A1MAPTLMNACYP2C19CYP2C9
SCHEMBL3540449 0.84 ALDH1A1 (0.60) ALDH1A1MAPTLMNACYP2C19NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885MAPT 159/4885LMNA 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.